Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2022 08:00 ET | Source: NextCure

NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation

BELTSVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
June 27, 2022 08:00 ET | Source: NextCure

NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
June 22, 2022 08:00 ET | Source: NextCure

Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting

BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
June 08, 2022 08:00 ET | Source: NextCure

NextCure to Present at the JMP Securities Life Sciences Conference

BELTSVILLE, Md., June 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
May 05, 2022 16:05 ET | Source: NextCure

NextCure Provides Business Update and Reports First Quarter 2022 Financial Results

On track to report data from all three clinical programs in the second half of 2022First quarter ending cash of $201.3 million expected to fund operations into the first quarter of 2024 ...
May 03, 2022 08:00 ET | Source: NextCure

NextCure to Present at the BofA Securities 2022 Healthcare Conference

BELTSVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
April 19, 2022 07:30 ET | Source: NextCure

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

BELTSVILLE, Md., April 19, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
April 05, 2022 08:00 ET | Source: NextCure

NextCure to Present at 21st Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
March 03, 2022 16:05 ET | Source: NextCure

NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Multiple data readouts expected in 2022, including updates for all three clinical programs Ends 2021 with cash position of $219.6 million that is expected to fund operations into first quarter of...
February 08, 2022 08:00 ET | Source: NextCure

NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference

BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...